【摘要】 目的:评估真实世界中维迪西妥单抗对比吉西他滨/顺铂(Gemcitabine/Cisplatin, GC)方案联合免疫治疗在膀胱癌保膀胱治疗中的疗效和安全性。方法:本研究是单中心真实世界的回顾性研究，连续纳入2023年3月—2024年3月于福建医科大学附属第一医院接受维迪西妥单抗联合免疫治疗和GC方案联合免疫治疗的33例膀胱癌患者的临床资料，分为A组(维迪西妥单抗联合免疫治疗)和B组(GC方案联合免疫治疗)。治疗后行影像学检查及二次根治性经尿道膀胱肿瘤电切术(transurethral resection of bladder tumor, TURBT)评估靶病灶变化情况。对比分析2组患者的病理完全缓解(pathological complete response, pCR)率、病理降期率、保膀胱率及预后情况，同时评估用药期间患者所发生的不良事件(adverse events, AEs)。结果:A组共纳入21例患者，其中16例选择保膀胱方案，5例选择膀胱根治切除术，中位随访时间9个月；B组共纳入12例患者，其中5例选择保膀胱方案，7例选择膀胱根治切除术，中位随访时间6个月。A组pCR率为52.4%(11/21),B组的pCR率为16.7%(2/12),差异有统计学意义(P=0.047);A组的病理降期率为81.0%(17/21),B组的病理降期率为58.3%(7/12),差异无统计学意义(P=0.159)。A组的保膀胱率为76.2%(16/21),B组的保膀胱率为41.7%(5/12),差异无统计学意义(P=0.055)。维迪西妥单抗联合免疫治疗常见的AEs包括高甘油三酯血症14例(66.7%)、血糖升高12例(57.1%)、肾功能减退10例(47.6%)等，其中3～4级AEs 3例(14.3%)。GC方案联合免疫治疗常见的AEs包括贫血7例(58.3%)、白细胞减少6例(50.0%)、肾功能减退5例(41.7%)、AST升高5例(41.7%)等，其中3～4级AEs 2例(16.7%)。结论:在膀胱癌治疗中，维迪西妥单抗联合免疫治疗较传统的GC方案联合免疫治疗具有更高的pCR率，病理降期率和保留膀胱率相仿，严重不良反应发生率低，且经治疗明显好转，在HER-2阴性的患者中亦有较好疗效。更多还原

【Abstract】 Objective: To evaluate the efficacy and safety of Disitamab Vedotin compared with Gemcitabine/Cisplatin(GC) regimen combined with immunotherapy in the bladder-preserving treatment of bladder cancer in the real-world setting. Methods: This single-center retrospective study included 33 bladder cancer patients treated between March 2023 and March 2024 at the First Affiliated Hospital of Fujian Medical University. Patients received either Disitamab Vedotin combined with immunotherapy(Group A) or GC regimen combined with immunotherapy(Group B). Post-treatment imaging evaluations and secondary rigorous radical transurethral resection of bladder tumor(TURBT) at the original tumor site were performed to assess changes in target lesions. Pathological complete response(pCR), pathological downstaging rate, bladder preservation rate, and prognosis were compared between the two groups. Adverse events(AEs) during treatment were also evaluated. Results: Group A included 21 patients, with 16 opting for bladder-preserving treatment and 5 undergoing radical cystectomy, with an average follow-up of 9 months. Group B included 12 patients, with 5 opting for bladder preservation and 7 undergoing radical cystectomy, with an average follow-up of 6 months. The pCR rate was 52.4%(11/21) in Group A and 16.7%(2/12) in Group B(P=0.047). Pathological downstaging rates were 81.0%(17/21) in Group A and 58.3%(7/12) in Group B(P=0.159). Bladder preservation rates were 76.2%(16/21) in Group A and 41.7%(5/12) in Group B(P=0.055). Common AEs during Disitamab Vedotin combined with immunotherapy included hypertriglyceridemia in 14 cases(66.7%), hyperglycemia in 12 cases(57.1%), and renal dysfunction in 10 cases(47.6%), with grade 3-4 AEs in 3 cases(14.3%). Common AEs during GC regimen combined with immunotherapy included anemia in 7 cases(58.3%), leukopenia in 6 cases(50.0%), renal dysfunction in 5 cases(41.7%), and AST elevation in 5 cases(41.7%), with grade 3-4 AEs in 2 cases(16.7%). Conclusion: In bladder cancer treatment, Disitamab Vedotin combined with immunotherapy showed higher pCR rate compared to the traditional GC regimen combined with immunotherapy, similar pathological downstaging rate and bladder preservation success rate, lower incidence of severe adverse reactions, and significant therapeutic improvement, even in HER-2 negative patients.更多还原